Immuron Partners with InvestorHub for Digital Engagement
PorAinvest
miércoles, 27 de agosto de 2025, 10:53 am ET1 min de lectura
IMRN--
The new partnership will see Immuron launch its interactive investor hub, an integrated platform where investors can access a variety of content, including videos, educational materials, interviews, and corporate research. The platform will also facilitate regular updates and new content uploads, ensuring investors are well-informed about the company's developments and milestones.
Steven Lydeamore, Chief Executive Officer of Immuron, commented, "With several near-term milestones coming up, there has never been a better time to launch an initiative to improve our communication with shareholders and the investment community. During the remainder of this calendar year, Immuron anticipates submission and approval by the FDA of IMM-529 Investigational New Drug (IND) submission and topline results released by the Uniformed Services University for the Travelan® (IMM-124E) clinical trial."
The partnership with InvestorHub is a significant step for Immuron in its commitment to better inform and engage with investors and stakeholders. By leveraging InvestorHub's digital capabilities, Immuron aims to create a more interactive and transparent communication channel, fostering a stronger relationship with its investor base.
To sign up for the Immuron investor hub, investors can visit [https://investors.immuron.com.au/s/5d454f](https://investors.immuron.com.au/s/5d454f) and follow the prompts to create an account.
References:
[1] https://www.globenewswire.com/news-release/2025/08/27/3139698/37134/en/Immuron-partners-with-InvestorHub.html
Immuron has entered a partnership with InvestorHub, a company that provides public companies with digital capabilities to engage directly with investors. Immuron will use the platform to upload content, including videos, educational material, and interviews. The partnership aims to enhance Immuron's investor relations and provide investors with a more interactive experience.
Melbourne, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) – Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of infectious diseases, has entered into a strategic partnership with InvestorHub. This partnership aims to enhance Immuron's investor relations by providing a digital platform for direct and interactive engagement with investors.The new partnership will see Immuron launch its interactive investor hub, an integrated platform where investors can access a variety of content, including videos, educational materials, interviews, and corporate research. The platform will also facilitate regular updates and new content uploads, ensuring investors are well-informed about the company's developments and milestones.
Steven Lydeamore, Chief Executive Officer of Immuron, commented, "With several near-term milestones coming up, there has never been a better time to launch an initiative to improve our communication with shareholders and the investment community. During the remainder of this calendar year, Immuron anticipates submission and approval by the FDA of IMM-529 Investigational New Drug (IND) submission and topline results released by the Uniformed Services University for the Travelan® (IMM-124E) clinical trial."
The partnership with InvestorHub is a significant step for Immuron in its commitment to better inform and engage with investors and stakeholders. By leveraging InvestorHub's digital capabilities, Immuron aims to create a more interactive and transparent communication channel, fostering a stronger relationship with its investor base.
To sign up for the Immuron investor hub, investors can visit [https://investors.immuron.com.au/s/5d454f](https://investors.immuron.com.au/s/5d454f) and follow the prompts to create an account.
References:
[1] https://www.globenewswire.com/news-release/2025/08/27/3139698/37134/en/Immuron-partners-with-InvestorHub.html

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios